Candel Therapeutics increased its Board of Directors from ten to eleven members and appointed Martine Zimmermann, Pharm.D., as an independent director effective September 8, 2026. Dr. Zimmermann joins the Class III slate with a term expiring at the 2027 Annual Meeting. Her compensation includes a $40,000 annual retainer paid quarterly and an option to purchase 64,000 shares vesting monthly over three years. The appointment adds regulatory and quality expertise as the company prepares for a planned Biologics License Application submission in late 2026. Candel Therapeutics is a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer treatment.

Candel Therapeutics, Inc. filed an 8-K on September 9, 2026, to furnish an investor presentation under Regulation FD. The presentation highlights positive Phase 3 results for aglatimagene in prostate cancer and Phase 2a data for NSCLC and pancreatic cancer. It confirms a $130 million term loan with Trinity Capital (October 2025) and a $100 million royalty funding agreement with RTW Investments (February 2026). The company reported $201.6 million in cash as of June 30, 2026, providing runway into Q1 2028. Candel Therapeutics operates in the biotechnology industry, developing immunotherapies for cancer.

Candel Therapeutics reported a net loss of $38.9 million for the quarter ended June 30, 2026, compared to a $4.8 million loss in the prior year period. Cash and cash equivalents stood at $201.6 million as of June 30, 2026, sufficient to fund operations into Q1 2028. The company plans to submit a Biologics License Application for aglatimagene besadenovec in localized prostate cancer in Q4 2026. Pivotal phase 3 data showed a 39% improvement in disease-free survival with the drug plus radiotherapy versus radiotherapy alone. Additionally, Candel activated its first trial site for the AURORA phase 3 trial of aglatimagene in non-squamous NSCLC and appointed Mark Sims as Chief Commercial Officer. The company operates in the biopharmaceutical industry, developing multimodal immunotherapies to improve outcomes for patients with cancer.

Candel Therapeutics, Inc. entered into a new employment agreement with Chief Financial Officer Charles Schoch on June 12, 2026. The agreement provides for an annual base salary of $468,600 and a target annual bonus of 40% of his base salary, along with severance-related benefits and equity acceleration in the event of a change in control. Candel Therapeutics, Inc. is a biotechnology company focused on developing oncology-related therapies.